Drugs / etonorgestrel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01920022 | Oct 2013 → Oct 2015 | — | Karolinska Institutet | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01397097 Comparator | Sep 2011 → Jun 2013 | — | Bayer | Completed | Met primary |
| Phase 4 | NCT01384331 Comparator | Jul 2011 → Dec 2012 | menstrual disorder | Family Planning Association New South Wales | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etonorgestrel | “21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days” NCT01384331 ↗ |
| Known as | Nexplanon | “68 mg etonorgestrel implant for subdermal use (Nexplanon)” NCT01397097 ↗ |